TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers

Stopped early · Phase 4

Conditions studied: Diabetic Foot Ulcers

In brief

The purpose of this study is to compare the clinical outcomes of TruSkin® and an Active Comparator in patients with chronic diabetic foot ulcers.

Key facts

Study ID

NCT02936115

Run by

Osiris Therapeutics

People needed

14

Starts

2016-07-01

Expected to finish

2017-04-01

Last updated by the study team

2017-04-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between 18 years and 80 years of age inclusive, as of the date of screening
• Confirmed diagnosis of Type 1 or Type 2 Diabetes
• An Index Ulcer that is chronic (defined as present for > 4 weeks, but not present for more than 52 weeks at the Screening Visit)
• Index Ulcer is located below the malleolus
• The Index Ulcer is a Diabetic Foot Ulcer (DFU) greater than 3 cm2, inclusive, at the Screening Visit
• The longest length and longest width measurements for the Index Ulcer are no less than 1 cm each at the Screening Visit
• The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule
• Wound is free of necrotic debris
• Patient has adequate circulation to the foot as documented by ABI or TBI

You may not qualify if…

• Index Ulcer is of non-diabetic pathophysiology
• Gangrene is present on any part of the affected foot
• Index Ulcer is over a Charcot deformity
• Patient is currently receiving dialysis or planning to go on dialysis
• Patient has a glycated hemoglobin A1c (HbA1c) level of >12%
• Chronic oral steroid use >7.5 mg daily for longer than 3 months at the time of screening
• Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening
• Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening
• Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
• Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
• Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site
• Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening
• Patient has active malignancy other than non-melanoma skin cancer
• Patient's Index Ulcer has decreased by ≥ 20% during 1-week screening period
• Patient's random blood sugar is > 450 mg/dl at screening
• Patient is unable to properly off-load the index wound as a part of standard of care
• Patient has untreated alcohol or substance abuse at the time of screening
• Pregnant women and women who are breastfeeding
• Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
• Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
• Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
• Patients who have already been randomized in Protocol 351 at any center may not be considered for screening or for re-entry into the trial at any center, even after the End of Study Visit
• Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol

Where it is running

• Study site — Florida City, Florida, United States
• Study site — Illinois City, Illinois, United States
• Study site — Michigan, Michigan, United States
• Study site — Texas City, Texas, United States
• Study site — Virginia City, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.